Trials / Completed
CompletedNCT00643994
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 379 (actual)
- Sponsor
- Accuray Incorporated · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.
Detailed description
The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | CyberKnife Stereotactic Radiosurgery | 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2021-01-27
- Completion
- 2021-01-27
- First posted
- 2008-03-26
- Last updated
- 2023-05-09
- Results posted
- 2023-05-09
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00643994. Inclusion in this directory is not an endorsement.